Literature DB >> 25744701

Prevention of vasculopathy by vitamin K supplementation: can we turn fiction into fact?

Vincent M Brandenburg1, Leon J Schurgers2, Nadine Kaesler3, Katrin Püsche4, Rick H van Gorp2, Georges Leftheriotis5, Sebastian Reinartz6, Ralf Koos4, Thilo Krüger3.   

Abstract

With the discovery that vitamin K-dependent matrix Gla-protein (MGP) is a strong and modifiable factor in the prevention of arterial calcification, vitamin K was put forward as novel treatment option in cardiovascular disease. The vasculoprotective properties of vitamin K are in part based on the ability to improve gamma-glutamylcarboxylation of MGP, which is a prerequisite for MGP as a calcification inhibitor. Data from experimental animal models reveal that high intake of vitamin K can prevent and even reverse vascular calcifications. In addition, clinical data demonstrate that prescription of vitamin K antagonists for long-term oral anticoagulant therapy accelerates vascular calcification. However, controlled data from randomized prospective vitamin K interventional trials are lacking, thereby weakening a general recommendation for supplementation. The present article summarizes our current knowledge on the association between vitamin K and cardiovascular health. Additionally, we focus on an outlook on important ongoing prospective vitamin K intervention studies. These studies address the issues whether vitamin K substitution helps modifying relevant cardiovascular surrogates such as vascular calcification and whether non-vitamin K oral anticoagulants provide an alternative to support cardiovascular health benefits. So research about cardiovascular protection by vitamin K is an evolving field in which we expect a boost of novel and relevant evidence shortly.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anticoagulation; Arteriosclerosis; Matrix-gla protein; Vascular calcification; Vitamin K

Mesh:

Substances:

Year:  2015        PMID: 25744701     DOI: 10.1016/j.atherosclerosis.2015.02.040

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  15 in total

1.  A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors.

Authors:  Sagar U Nigwekar; Sophia Zhao; Julia Wenger; Jeffrey L Hymes; Franklin W Maddux; Ravi I Thadhani; Kevin E Chan
Journal:  J Am Soc Nephrol       Date:  2016-04-14       Impact factor: 10.121

Review 2.  Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation.

Authors:  Gunnar H Heine; Vincent Brandenburg; Stephan H Schirmer
Journal:  Dtsch Arztebl Int       Date:  2018-04-27       Impact factor: 5.594

3.  High-Dose Menaquinone-7 Supplementation Reduces Cardiovascular Calcification in a Murine Model of Extraosseous Calcification.

Authors:  Daniel Scheiber; Verena Veulemans; Patrick Horn; Martijn L Chatrou; Sebastian A Potthoff; Malte Kelm; Leon J Schurgers; Ralf Westenfeld
Journal:  Nutrients       Date:  2015-08-18       Impact factor: 5.717

4.  Menaquinone-7 Supplementation to Reduce Vascular Calcification in Patients with Coronary Artery Disease: Rationale and Study Protocol (VitaK-CAC Trial).

Authors:  Liv M Vossen; Leon J Schurgers; Bernard J van Varik; Bas L J H Kietselaer; Cees Vermeer; Johannes G Meeder; Braim M Rahel; Yvonne J M van Cauteren; Ge A Hoffland; Roger J M W Rennenberg; Koen D Reesink; Peter W de Leeuw; Abraham A Kroon
Journal:  Nutrients       Date:  2015-10-28       Impact factor: 5.717

5.  The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials.

Authors:  Rogier Caluwé; Lotte Pyfferoen; Koen De Boeck; An S De Vriese
Journal:  Clin Kidney J       Date:  2015-12-29

6.  CDKN2A/p16INK4a expression is associated with vascular progeria in chronic kidney disease.

Authors:  Peter Stenvinkel; Karin Luttropp; Dagmara McGuinness; Anna Witasp; Abdul Rashid Qureshi; Annika Wernerson; Louise Nordfors; Martin Schalling; Jonaz Ripsweden; Lars Wennberg; Magnus Söderberg; Peter Bárány; Hannes Olauson; Paul G Shiels
Journal:  Aging (Albany NY)       Date:  2017-02-09       Impact factor: 5.682

7.  Circulating phylloquinone, inactive Matrix Gla protein and coronary heart disease risk: A two-sample Mendelian Randomization study.

Authors:  Sabine R Zwakenberg; Stephen Burgess; Ivonne Sluijs; Elisabete Weiderpass; Joline W J Beulens; Yvonne T van der Schouw
Journal:  Clin Nutr       Date:  2019-05-07       Impact factor: 7.643

Review 8.  New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs).

Authors:  Rick H van Gorp; Leon J Schurgers
Journal:  Nutrients       Date:  2015-11-17       Impact factor: 5.717

9.  The Effects of Parenteral K1 Administration in Pseudoxanthoma Elasticum Patients Versus Controls. A Pilot Study.

Authors:  Juan Luis Carrillo-Linares; María Inmaculada García-Fernández; María José Morillo; Purificación Sánchez; José Rioja; Francisco Javier Barón; María José Ariza; Dominic J Harrington; David Card; Federica Boraldi; Daniela Quaglino; Pedro Valdivielso
Journal:  Front Med (Lausanne)       Date:  2018-04-16

10.  A Novel Biomimetic Tool for Assessing Vitamin K Status Based on Molecularly Imprinted Polymers.

Authors:  Kasper Eersels; Hanne Diliën; Joseph W Lowdon; Erik Steen Redeker; Renato Rogosic; Benjamin Heidt; Marloes Peeters; Peter Cornelis; Petra Lux; Chris P Reutelingsperger; Leon J Schurgers; Thomas J Cleij; Bart van Grinsven
Journal:  Nutrients       Date:  2018-06-11       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.